Aripiprazole: Difference between revisions

From Citizendium
Jump to navigation Jump to search
imported>David E. Volk
(Chemical structure and chem infobox)
m (Text replacement - "United States" to "United States of America")
Line 20: Line 20:
In [[medicine]], '''aripiprazole''' (pronunciation: ay ri pip' ray zole) is an atypical or second generation [[antipsychotic agent]] that "has both presynaptic [[dopamine]] autoreceptor agonistic activity and  postsynaptic D<sub>2</sub> receptor antagonistic activity; structure given in first  source; use associated with hyperglycemia."<ref>{{MeSH}}</ref>
In [[medicine]], '''aripiprazole''' (pronunciation: ay ri pip' ray zole) is an atypical or second generation [[antipsychotic agent]] that "has both presynaptic [[dopamine]] autoreceptor agonistic activity and  postsynaptic D<sub>2</sub> receptor antagonistic activity; structure given in first  source; use associated with hyperglycemia."<ref>{{MeSH}}</ref>


In the [[United States]], the [[Food and Drug Administration]] has approved the use of aripiprazole for the treatment of [[schizophrenia]], [[bipolar disorder|bipolar I disorder]], [[major depressive disorder]], irritability associated with [[autistic disorder]] agitation associated with [[schizophrenia]] or mania from [[bipolar disorder]]. It is also approved as an adjunct to antidepressants.<ref>{{citation
In the [[United States of America]], the [[Food and Drug Administration]] has approved the use of aripiprazole for the treatment of [[schizophrenia]], [[bipolar disorder|bipolar I disorder]], [[major depressive disorder]], irritability associated with [[autistic disorder]] agitation associated with [[schizophrenia]] or mania from [[bipolar disorder]]. It is also approved as an adjunct to antidepressants.<ref>{{citation
| title = Beneficial acute antidepressant effects of aripiprazole as an adjunctive treatment or monotherapy in bipolar patients unresponsive to mood stabilizers: results from a 16-week open-label trial
| title = Beneficial acute antidepressant effects of aripiprazole as an adjunctive treatment or monotherapy in bipolar patients unresponsive to mood stabilizers: results from a 16-week open-label trial
| date = December 2008 | volume = 9 | issue = 18 | pages = 3145-3149 | doi =10.1517/14656560802504490
| date = December 2008 | volume = 9 | issue = 18 | pages = 3145-3149 | doi =10.1517/14656560802504490

Revision as of 11:50, 2 February 2023

This article is a stub and thus not approved.
Main Article
Discussion
Related Articles  [?]
Bibliography  [?]
External Links  [?]
Citable Version  [?]
 
This editable Main Article is under development and subject to a disclaimer.
Aripiprazole.png
Aripiprazole
IUPAC name: 7-[4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy]-3,4-dihydrocarbostyril
Synonyms:
Formula: C23H27Cl2N3O2

 Uses: antipsychotic agent

 Properties: medication

 Hazards: see side effects & drug interactions

Mass (g/mol): CAS #:
448.38



In medicine, aripiprazole (pronunciation: ay ri pip' ray zole) is an atypical or second generation antipsychotic agent that "has both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity; structure given in first source; use associated with hyperglycemia."[1]

In the United States of America, the Food and Drug Administration has approved the use of aripiprazole for the treatment of schizophrenia, bipolar I disorder, major depressive disorder, irritability associated with autistic disorder agitation associated with schizophrenia or mania from bipolar disorder. It is also approved as an adjunct to antidepressants.[2] The trade name is Abilify™. Although not approved for the treatment of dementia, aripiprazole has been studied in this setting.

References

  1. Anonymous (2024), Aripiprazole (English). Medical Subject Headings. U.S. National Library of Medicine.
  2. Marianna Mazza, Maria Rosaria Squillacioti1, Riccardo Daniele Pecora, Luigi Janiri1 & Pietro Bria (December 2008), "Beneficial acute antidepressant effects of aripiprazole as an adjunctive treatment or monotherapy in bipolar patients unresponsive to mood stabilizers: results from a 16-week open-label trial", Expert Opinion on Pharmacotherapy 9 (18): 3145-3149, DOI:10.1517/14656560802504490